American Renal Associates Holdings, Inc. (NYSE:ARA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

American Renal Associates Holdings, Inc. (NYSE:ARA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02

Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers

As previously disclosed, on November 10, 2016, American Renal
Associates Holdings, Inc., (the Company) announced that John J.
McDonough agreed to step down from his role as Executive Vice
President, Chief Operating Officer and Treasurer of the Company,
effective December 31, 2016 (the Separation Date).

In connection with Mr. McDonoughs departure, on December 21,
2016, the Company entered into a Severance Agreement with Mr.
McDonough (the Separation Agreement). As part of the Separation
Agreement,Mr. McDonough has agreed to provide transition
consulting services to the Company from January 1, 2017 through
June 30, 2017, on an as-needed basis as requested by Joseph
Carlucci or Jonathan Wilcox.In addition, the Separation Agreement
provides that:

Mr. McDonough will receive those benefits set forth for a
termination by the Company without Cause or resignation
by Mr. McDonough for Good Reason for purposes of his
Employment Agreement with the Company dated March 22,
2010, as amended from time to time, and for purposes of
the outstanding long-term incentive award agreements to
which Mr. McDonough is a party; and

subject to Mr. McDonoughs providing consulting services,
79,721 stock options granted on July 9, 2010 will remain
outstanding and eligible to vest through March 22, 2018.

The foregoing payments and benefits are subject to an execution
of a valid release of claims by Mr. McDonough and his compliance
with certain restrictive covenants.

The foregoing description is qualified by reference to the full
text of the Separation Agreement, which is filed as Exhibit10.1
attached hereto and is incorporated by reference in its entirety
into this Item 5.02.

Item9.01.

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

10.1

Severance Agreement dated as of December 21, 2016 entered
into between the Company and John McDonough.


About American Renal Associates Holdings, Inc. (NYSE:ARA)

American Renal Associates Holdings, Inc. is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD). It operates clinics through a joint venture (JV) model, in which it partners with local nephrologists to develop, own and operate dialysis clinics. Each of its clinics is maintained as a separate joint venture in which it has the controlling interest, and its nephrologist partners and other joint venture partners have a non-controlling interest. The Company opens over 20 de novo clinics each year. The Company has owned and operated over 190 dialysis clinics in partnership with approximately 350 nephrologist partners treating over 13,000 patients in over 20 states and the District of Columbia.

American Renal Associates Holdings, Inc. (NYSE:ARA) Recent Trading Information

American Renal Associates Holdings, Inc. (NYSE:ARA) closed its last trading session down -0.17 at 22.11 with 67,809 shares trading hands.